Intranasal delivery of pneumococcal polysaccharide vaccines
AssigneeAventis Pasteur Limited
InventorIngileif Jonsdottir
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for preventing against diseases induced by Streptococcus pneumoniae infections, which comprises mucosally administering to a patient in need of a S. pneumoniae capsular polysaccharide. This latter may be conjugated or not and is preferably mixed with a mucosal adjuvant such as cholera toxin, E. coli heatlabile toxin or Rhinovax™. A preferred route of administration is the intranasal route.
Claims17
A method of preventing S. pneumococcus infection comprising mucosally administering to a human a composition comprising an S. pneumococcus capsular polysaccharide in an amount effective to prevent S. pneumococcus infection in a human.
A composition comprising S. pneumococcus capsular polysaccharide and a mucosal adjuvant.
Dependencies are inferred from the claim text.